🔴 Liquidia Technologies is trading 22.7% down after court finds YUTREPIA infringed two patent claims

Liquidia Technologies is trading 22.7% down at $23.39 after a Delaware federal court found YUTREPIA infringed two valid United Therapeutics patent claims covering treatment of pulmonary hypertension associated with interstitial lung disease.

• The ruling could lead to an order affecting YUTREPIA’s FDA approval or PH-ILD indication; United Therapeutics intends to seek damages.
• The parties have one week to submit a proposed final judgment.
• Shares also fell 57.19% on September 30, closing at $30.26.